Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Platform study of GHZ339 versus topical calcineurin inhibitors and placebo in moderate to severe atopic dermatitis
2024-519081-49-00Phase 2Authorised
- Sponsor
- Novartis
- Start
- Sep 2025
- Countries
- 18
01
Overview
Phase 2, randomised, double-blind trial of GHZ339 in atopic dermatitis (AD) (4 arms), sponsored by Novartis. Planned start Sep 2025; status: authorised.
02
Drugs
GHZ339
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2024-519081-49-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519081-49-00.